How could AMA's push for stricter botanical product regulation affect the Center for Drug Evaluation and Research?
Stricter standards may require Center for Drug Evaluation and Research updates AMA is urging the Food and Drug Administration to regulate botanical products, such as those derived from kratom and cannabis, to the same scientific standards used for conventional drugs. If the FDA adopts these standards, the Center for Drug Evaluation and Research would need to update its scientific review processes and operational rules. This shift would require the center to rigorously determine the efficacy and safety of these botanical products through research and clinical trials, moving away from the current status where 'natural' is not considered a safety standard.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within months
- The story
- Still developing
How it reaches Center for Drug Evaluation and Research
-
The American Medical Association sent a letter to the Food and Drug Administration urging increased regulation of botanical products. The AMA recommends that the FDA hold products derived from substances such as cannabis and kratom to the same scientific standards used for conventional drugs. The AMA noted that consumers are facing risks, including dependence and overdose, from these products being used without research-based evidence.
The full event1independent outlet -
If the FDA adopts these stricter standards, the Center for Drug Evaluation and Research, as a key research division, would be required to update its protocols. This would involve determining the efficacy and safety of botanical products through research and clinical trials, as AMA recommends, to ensure they meet rigorous scientific standards.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
FDA research center
Everything about Center for Drug Evaluation and Research
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- AMA wants the FDA to hold botanical products derived from substances such as cannabis and kratom to the same scientific standards they maintain for approving other conventional drugs.healio.com
- AMA strongly recommends the FDA regulate them and determine their efficacy through research and clinical trials.healio.com
- Anita Gupta noted that 'natural is simply a marketing word, not a safety standard.'healio.com
- Healio previously reported the number of poison control calls related to kratom exposure increased 1,200% between 2015 and 2025.healio.com
Why it matters
The stakes revolve around consumer safety and the integrity of drug regulation. Currently, many botanical products are used by consumers to self-treat conditions like anxiety, pain, and depression, but they lack the rigorous scientific vetting of approved medications. AMA warns that consumers are becoming 'real-world guinea pigs' due to the lack of research-based evidence for these potent products.
This push aligns with concerns raised by medical professionals, such as Anita Gupta, who stressed that botanicals must be treated as drugs that belong on a medication list. The movement seeks to apply the same level of scientific scrutiny used for conventional pharmaceuticals to substances like kratom and cannabis, which have shown varied effects in clinical settings.
What we don't know yet
- What specific regulatory changes would the FDA implement if it adopted AMA's recommendations?
- How would the FDA allocate the necessary funding and resources for expanded clinical research on botanical products?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
- Drug Enforcement AdministrationLikelyDEA may face increased enforcement demands as FDA considers stricter botanical drug rules
- CongressPossibleCongress may face pressure to adjust FDA scope and funding for botanical products
- Eli Lilly and CompanyPossibleStricter FDA standards could increase compliance costs for Eli Lilly and Company
- Department of Health & Human ServicesPossibleHHS oversight may increase as AMA pushes for stricter botanical drug regulation
- Heidi OvertonPossibleThe FDA Commissioner may face pressure to adopt stricter scientific standards for botanical products.
Reporting
- healio.comYesterday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.